{
  "abstract": "Introduction: Patients with cancer are at increased risk of morbidity and mortality from COVID-19 but were underrepresented in pivotal vaccine trials. Data on the magnitude and determinants of immune responses to mRNA SARS-CoV-2 vaccination in this population remain limited. Methods: I-SPARC is a prospective, phase IV clinical trial evaluating humoral and cellular immune responses to mRNA SARS-CoV-2 vaccination in 115 patients with cancer, including those receiving systemic therapy and those in remission. Anti-Spike antibody titers were measured longitudinally, and immunophenotyping was performed to assess T and B cell subsets. Clinical outcomes, including SARS-CoV-2 infection, were recorded. Results: All patients developed detectable anti-Spike antibodies, although absolute titers varied by cancer type and treatment. Patients with hematologic malignancies and/or receiving chemotherapy had the lowest anti-Spike antibody levels. Booster doses significantly increased titers, particularly in patients in remission or receiving non-cytotoxic therapies. Prior SARS-CoV-2 infection and the number of vaccine doses were associated with better responses. Immunophenotyping confirmed vaccine-induced expansion of memory T and B lymphocyte subpopulations. SARS-CoV-2 infection occurred in 16% of our cohort, with infrequent severe cases. Discussion: mRNA SARS-CoV-2 vaccines elicit robust humoral and cellular immune responses in patients with cancer, despite variability according to disease type and treatment. These findings support the use of booster strategies and provide a rationale for tailored vaccination approaches in immunocompromised populations.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 25,
  "authors": [
    {
      "name": "Soraia Lobo-Martins"
    },
    {
      "name": "Diogo Martins-Branco"
    },
    {
      "name": "Francine Padonou"
    },
    {
      "name": "Hafid Dahma"
    },
    {
      "name": "Sigi van den Wijngaert"
    },
    {
      "name": "Mounia Jaouart"
    },
    {
      "name": "Chiara Dauccia"
    },
    {
      "name": "Chiara Molinelli"
    },
    {
      "name": "Elisa Agostinetto"
    },
    {
      "name": "Angela Loizidou"
    },
    {
      "name": "Donatienne Taylor"
    },
    {
      "name": "Anais Boisson"
    },
    {
      "name": "Soizic Garaud"
    },
    {
      "name": "Chloé Spilleboudt"
    },
    {
      "name": "Jose Vicente Cardona"
    },
    {
      "name": "Peter Ramge"
    },
    {
      "name": "Bogdana Ioana Balas"
    },
    {
      "name": "Mohammed Bajji"
    },
    {
      "name": "Fanny George"
    },
    {
      "name": "Tabatha Delsaute"
    },
    {
      "name": "Marianne Paesmans"
    },
    {
      "name": "Lieveke Ameye"
    },
    {
      "name": "Martine Piccart"
    },
    {
      "name": "Evandro de Azambuja"
    },
    {
      "name": "Karen Willard-Gallo"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/dbcx7m1rdwd40.bib",
  "cited_by": 1,
  "doi": "10.3389/fimmu.2026.1815933",
  "fulltext_url": null,
  "id": "dbcx7m1rdwd40",
  "issns": [
    "1664-3224",
    "1664-3224"
  ],
  "landing_url": "https://hal.science/hal-05772320v1",
  "language": "en",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "hal",
      "0.sdv"
    ],
    [
      "hal",
      "1.sdv.imm"
    ],
    [
      "openalex",
      "2725|SARS-CoV-2 and COVID-19 Research"
    ]
  ],
  "openalex": "W7161790692",
  "pdf_url": "https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1815933/pdf",
  "pmcid": null,
  "pmid": "42245650",
  "published": "2026-05-20",
  "publisher": "Frontiers",
  "ris": "https://research.draconitic.com/paper/dbcx7m1rdwd40.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:44Z",
      "native_id": "hal-05772320",
      "source": "hal",
      "url": "https://hal.science/hal-05772320v1"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "hal:1.sdv.imm",
      "subfield": "immunology"
    }
  ],
  "title": "Long-term immune response to mRNA anti-SARS-CoV-2 vaccination in patients with cancer",
  "title_text": "Long-term immune response to mRNA anti-SARS-CoV-2 vaccination in patients with cancer",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:17:44Z",
  "url": "https://research.draconitic.com/paper/dbcx7m1rdwd40",
  "venue": "Frontiers in Immunology",
  "versions": []
}